AZ Restructures, But Will Changes Sideline Plans To Accelerate R&D?
AstraZeneca unveiled an R&D restructuring March 18 that will consolidate research to three locations and reduce headcount by 1,600, but the company will have to be dogged in its effort to relocate key employees if it is to ensure the changes don’t disrupt its broader goal of accelerating the pace of R&D.
You may also be interested in...
Once an R&D site for AstraZeneca, the BioHub at Alderley Park is now home to a number of emerging biotechs. Profiles of Absynth Biologics, Blueberry Therapeutics, Molplex, and OncoTherics.
The unique industrial collaboration with University College London will exploit in-depth knowledge of blood-flow biology to develop new products for CV disease, fetal growth retardation and melanoma.
Pharmaceutical and biotech companies in Europe take heart from IPOs and new governmental schemes to improve patients’ early access to innovative medicines, while fresh calls are made for an integrated, over-arching European industrial strategy for the life sciences sector.